BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Ovarian Cancer, Merkel Cell Carcinoma, SCLC

In brief

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.

Key facts

Study ID

NCT00346385

Run by

ImmunoGen, Inc.

People needed

97

Starts

2002-03-01

Expected to finish

2011-10-01

Last updated by the study team

2015-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California San Francisco — San Francisco, California, United States
• Nevada Cancer Institute — Las Vegas, Nevada, United States
• The Ohio State University Cancer Center and Research Institute — Columbus, Ohio, United States
• Oklahoma University — Oklahoma City, Oklahoma, United States
• M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
• Christie Hospital NHS Trust — Manchester, England, United Kingdom
• Cancer Research Centre at Weston Park Hospital — Sheffield, England, United Kingdom
• Royal Marsden NHS Foundation Trust - Surrey — Sutton, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.